Experimental Hematology
Volume 34, Issue 10 , Pages 1289-1295, October 2006

Chemokines in multiple myeloma

  • Rohit Aggarwal

      Affiliations

    • Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pa., USA
  • ,
  • Irene M. Ghobrial

      Affiliations

    • Division of Hematology, University of Pittsburgh, Pittsburgh, Pa., USA
  • ,
  • G. David Roodman

      Affiliations

    • Division of Hematology, University of Pittsburgh, Pittsburgh, Pa., USA
    • Corresponding Author InformationOffprint requests to: G. David Roodman, M.D., Ph.D., VA Pittsburgh Healthcare System, Research and Development (151U), University Drive C, Pittsburgh, PA 15240

Received 23 May 2006; received in revised form 27 June 2006; accepted 27 June 2006.

Objective

In this article we focus on the role that chemokines and chemokine receptors play in the pathogenesis of multiple myeloma and the associated bone destructive process, and consider their utility as novel therapeutic targets for treating this devastating disease.

Methods

Current research on the role that chemokine and chemokine receptors play in the pathogenesis of myeloma is reviewed.

Results

The chemokines, MIP-1α, MCP-1, IL-8, and SDF-1, and their receptors play important roles in homing of MM cells, tumor growth, and bone destruction in myeloma. They are attractive therapeutic targets for treating myeloma patients.

Conclusion

Addition of chemokine antagonists to current treatment regimens for myeloma should result in better therapeutic responses because of the loss of both the protective effect of the marrow microenvironment on the MM cells and the induction of osteoclast activity.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(06)00425-5

doi:10.1016/j.exphem.2006.06.017

Experimental Hematology
Volume 34, Issue 10 , Pages 1289-1295, October 2006